Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

计划入组 8,053 人 · 首次发布于 2001 年 9 月 10 日

The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis

计划入组 280 人 · 首次发布于 2024 年 8 月 30 日

Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

计划入组 3,400 人 · 首次发布于 2018 年 3 月 22 日

Tuberculosis,Uvax

tuberculosis vaccine

non-tuberculosis mycobacterial diseases/ tuberculosis therapy

KNCV TUBERCULOSIS FOUNDATION

Nigeria

TUBERCULOSIS RESEARCH CENTRE

India

BATEMAN, TIMOTHY M. M. MD

United States

Discovery of Arr-X: A Novel, Highly Efficient Rifamycin-Inactivating Enzyme Family Reveals New Antibiotic Resistance Mechanisms Across Mycobacteria

Experimental Cancer Drug Navitoclax Shows Promise in Enhancing Tuberculosis Treatment

IAVI and Biofabri Launch Phase 2a Trial of Novel Tuberculosis Vaccine in Adults and Adolescents